Medtronic submits final IN.PACT Admiral drug-coated balloon data to FDA Medtronic announced that it recently submitted the final module of its pre-market approval application for the IN.PACT Admiral drug-coated balloon to the U.S. Food and Drug Administration. The application includes data that demonstrates superior clinical outcomes compared with conventional angioplasty, with the lowest rates of repeat procedures and the highest rate of uninterrupted blood flow at 12 months ever reported for the interventional treatment of peripheral artery disease.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: Arc Logistics (ARCX) upgraded to Buy from Hold at Stifel... Dean Foods (DF) upgraded to Buy from Hold at Deutsche Bank... FreightCar America (RAIL) upgraded to Neutral from Sell at UBS... Frontier Communications (FTR) upgraded to Buy from Hold at Jefferies... Google (GOOG) upgraded to Outperform from Market Perform at BMO Capital... Intel (INTC) upgraded to Buy from Hold at Needham... Medtronic (MDT) upgraded to Buy from Neutral at BTIG... Netflix (NFLX) upgraded to Buy from Neutral at Rosenblatt... New Jersey Resources (NJR) upgraded to Buy from Hold at Argus... ONEOK Partners (OKS) upgraded to Outperform from Perform at Oppenheimer... Patterson-UTI (PTEN) upgraded to Overweight from Equal Weight at Morgan Stanley... SJM Holdings (SJMHY) upgraded to Overweight from Underweight at JPMorgan... Statoil (STO) upgraded to Buy from Neutral at Citi... SunOpta (STKL) upgraded to Outperform from Sector Perform at Scotia Howard Weil... Viacom (VIAB) upgraded to Neutral from Sell at Citi... Walgreens Boots Alliance (WBA) upgraded to Outperform from Neutral at Credit Suisse... Werner (WERN) upgraded on 'compelling' valuation at Wells Fargo... Wisconsin Energy (WEC) upgraded to Outperform from Neutral at Baird... voxeljet (VJET) upgraded to Overweight from Neutral at Piper Jaffray.
Medtronic upgraded to Buy from Neutral at BTIG BTIG upgraded Medtronic to Buy with a $89 price target. The firm believes the recent pullback has provided a buying opportunity and views the company as well positioned for growth with revenue upside, strong cash deployment, and more Covidien synergies than some expect.